The effects of the topical administration of non-steroidal anti inflammatory drugs on corneal epithelium and corneal sensitivity in normal subjects
(NSAIDs; diclofenac, indomethacin, flurbiprofen and ketorolad frequently used in ocular therapy_
Methods A double-masked parallel clinical study was undertaken on 90 subjects (45 men, 45 women; Caucasian; age 21--46 years, mean ::':: SD 27.1 ::':: 5 years). The subjects were divided into six groups: group 1 was treated with placebo, group 2 with 0.1% diclofenac, group 3 with 0.1% indomethacin, group 4 with 0.03% flurbiprofen, group 5 with 0.5% ketorolac and group 6 with 0.4% oxybuprocaine. One eye was randomly treated with the study drug and neuralgia,4-8 can affect corneal sensitivity. A decreased corneal sensitivity was also described after ocular surgical procedures such as epikeratophakia,9 radial keratotomylO and photo refractive keratectomy, II and topical treatment with NSAIOsY-I5 Diclofenac sodium is a phenylacetic acid derivative used, in clinical practice, for its analgesic properties. Indomethacin, a methylated indole derivative, exerts its action through a prominent anti-inflammatory activity. Indo methacin also has an analgesic effect distinct from its anti-inflammatory properties with both a central and peripheral action. Flurbiprofen is a propionic acid derivative with a prevalent analgesic effect. 16 Ketorolac tromethamine is a member of the phenylalkanoic group of NSAIDs, which has shown marked analgesic properties.I7 The aim of the study was to compare the effect of indomethacin, diclofenac, flurbiprofen and ketorolac on the corneal epithelium and on corneal sensitivity of healthy volunteers.
Material and methods
Ninety subjects (45 men, 45 women; Caucasian; age 21-46 years, mean ::':: SO 27.1 ::':: 5 years) were enrolled in the study. Commercially available drugs were used. Six groups each of 15 healthy volunteers, age and sex matched, were studied.
Group 1, the control group, was treated with placebo with the following solution: boric acid 99.75 mg, borax 7.45 mg, methyl-p-hydroxybenzoate 2.5 mg, polyethylene glycol 400 1242.50 mg, disodium edetate 2.5 mg, purified water quantum sufficit to 5 ml (mean age ::':: SO 28.7 ::':: 6.9 years; 8 women, 7 men).
Group 2 was treated with 0.1 % diclofenac (Voltaren Ofta, Ciba Vision Ophthalmics, Hettlingen, Switzerland) (26.2 ± 4 years; 7 women, 8 men).
Group 3 was treated with 0.1% indomethacin solution (Indocollirio, SIFI, Catania, Italy) (26.7 ::':: 3.6 years; 8 women, 7 men).
Group 4 was treated with 0.03% flurbiprofen (Ocufen, Allergan Pharmaceuticals, Westport, Co. Mayo, Ireland) (26.2 ± 3.3 years; 7 women, 8 men).
Group 5 was treated with 0.5% ketorolac tromethamine (Acular, Allergan Pharmaceuticals, Westport, Co. Mayo, Ireland) (24.9 ± 4 years; 8 women, 7 men).
Group 6 was treated with a topical anaesthetic solution of 0.4% oxybuprocaine chloridrate (Novesina, Novartis Farma, Orrigio (VA), Italy) (30 ::':: 6.1 years; 7 women, 8 men).
Informed consent was obtained from all subjects. Exclusion criteria were: age over 50 years, contact lens wear, and patients with present ocular diseases or with a history of diseases such as herpetic diseases or with previous ocular surgery. Also excluded were patients who had taken topical or general treatment during the previous month or with systemic diseases such as diabetes.
The eye drops were instilled in one eye 4 times at 5 min intervals and the ocular surface studied by fluorescein stainl8 before drug instillation and 5, 15,30 and 60 min after the last drop was instilled. The fellow eye was treated according to the same procedure, with the drop used in the placebo group. A subjective evaluation of the burning sensation was performed by asking participants to rate burning, after each instillation, on a scale ranging from 0 (none) to 3 (severe).
After 1 week the drugs were instilled again, following the same procedure previously described; the corneal sensitivity measurements were performed before the instillation and 5, 15, 30 and 60 min after instillation of the last drop, using the Cochet-Bonnet aesthesiometer (Luneau Ophtalmologie, Chartres, France). The instrument consists of a 0.12 mm diameter nylon filament of variable length (from 0 to 60 mm) which is applied on the cornea with a strength variable from 11 to 200 mg/ 0.0113 mm2 (mg/S). 19 The subjects were pOSitioned at the slit-lamp fixating on a distant point with the slit-lamp light positioned at about 60°, with low-intensity illumination. The measurements were started with the filament at its maximal length (lowest pressure), which is 60 mm. The filament was advanced perpendicularly and the cornea touched gently. Measurements were taken at the central cornea and in the four peripheral quadrants. A positive response was registered when the subject declared verbally the sensation of corneal touch. The simple reflex blinking of the tested eye was not recorded as a positive response. If a positive response was not achieved the filament length was reduced by 5 mm and the procedure repeated. The filament length that determined the corneal sensation was registered and converted into milligrams/surface unit (mg/S) according to a table supplied by the instrument manufacturer.
The study was performed with a double-masked design since both the subjects and the examiner were masked as to which eye received the drug.
For statistical analysis of the results of corneal epithelial damage Fisher's exact test was used; the results of corneal sensitivity (in mg/S) were carried out conSidering for each eye the mean value obtained from the measurements of the five areas considered. Analysis was performed using an analysis of variance. Results were expressed as the mean ::':: SO. A P value of � 0.05 was considered statistically significant.
Results
No signs of corneal epithelial damage were found in the patients of the five groups treated with placebo or with NSAIOs at any time of the study. Four subjects treated with the topical anaesthetic showed mild corneal epithelial defects (score 1 according to Lempl8) already present at 5 min after instillation of the last drop and lasting up to the observation at 60 min (p = 0.04).
All groups instilled with NSAIDs complained of a mild burning sensation lasting a few seconds after each instillation. The grading of the subjective burning (Fig. 1) .
The results of corneal sensitivity for the six treatment groups are shown in Table 1 . Before administration of the eye drops all subjects had corneal sensitivity values of
11-12 mg/S. A decrease in corneal sensitivity was
demonstrated in diclofenac-treated eyes at the measurement carried out 15 min after instillation of the last drop and lasting up to the end of the study. This was statistically significant when compared with either the treatment with other NSAIDs (Fig. 2) or the fellow eyes ( Table 1 ). The oxybuprocaine-treated subjects showed a profound reduction in corneal sensitivity (beyond the measurement capability of the instrument) 5 min after 
Discussion
The present study has shown a statistically significant decrease in corneal sensitivity in diclofenac-treated eyes.
This effect appeared at the measurement performed The corneal hypoaesthetic effect shown by diclofenac could be due also to a mechanism of action different from that of cyclooxygenase inhibition, since indomethacin, flurbiprofen and ketorolac did not demonstrate such an effect.
In this study, commercially available eye drops instead of hospital-manufactured solutions were used.
Although there were some differences in the vehicle present in the different solutions, it was decided to test the actual formulations that are prescribed to patients.
On the other hand previous reports have shown a good corneal penetration and efficacy in the anterior chamber and in the corneal stroma of the NSAIDs used in the present study, 28-30 and also an effect on the response of the corneal sensory nerve fibres to chemical irritation. 26 As to the effect on corneal epithelium, previous studies have shown that the topical administration of diclofenac induced a toxic effect on the corneal epithelium with a high incidence of persistent epithelial defects in post-keratoplasty patients, 31 while after photorefractive keratectomy delayed wound healing was demonstrated ? 2 These data are not in contrast with those of the present study, which showed a lack of epithelial toxicity consequent to the acute administration of diclofenac in normal subjects with a normal acute epithelium. It is noteworthy that even if diclofenac caused a reduction of corneal sensitivity this was not followed by epithelial damage, which was instead present in some patients following oxybuprocaine administration, This might be related to the greater imbalance of corneal sensitivity that followed administration of the topical anaesthetic.
As regards the duration of corneal hypoesthesia induced by diclofenac, previous reports showed various results using similar administration times, Szerenyi and In conclusion, the corneal hypoesthesia induced by diclofenac can be useful in reducing the pain and discomfort due to ocular inflammation and surgery.
However, further studies are needed to determine the safety, efficacy and mechanisms of action of topical diclofenac. In fact, in chronic treatment, the effect of diclofenac on corneal nerves could be responsible either for an increased healing time of the corneal epithelium or for a neurotrophic epitheliopathy in those patients with conditions predisposing to epithelial damage, such as dry eye.
